Utah Medical Products (UTMD) Q3 2024 earnings summary

Executive summary

• Q3 and 9M 2024 net sales declined 20% and 16% year-over-year, mainly due to lower OEM sales to PendoTECH and weaker Filshie Clip System sales.

• Despite lower revenues, operating income and profit margins remained stable or outperformed projections due to cost controls, headcount reductions, and reduced amortization expenses.

• Share repurchases and a lower tax provision rate helped mitigate the impact of lower earnings per share.

Financial highlights

• Q3 2024 net sales: $10.0M (down 20% YoY); 9M 2024 net sales: $31.7M (down 16% YoY).

• Q3 2024 net income: $3.6M (down 9% YoY); 9M 2024 net income: $11.0M (down 11% YoY).

• Q3 2024 diluted EPS: $1.02–$1.03 (down 5% YoY); 9M 2024 diluted EPS: $3.10 (down 8.7–9% YoY).

• Adjusted EBITDA for 9M 2024: $15.4M (down 25% YoY); margin 48.7%.

• Gross profit margin: 58.0% in Q3 2024 (vs. 58.8% prior year); operating income margin: 33.4% (vs. 31.7%).

Outlook and guidance

• 2024 revenue expected to decline 18–19% with a similar decline in net income; EPS to benefit from continued share repurchases.

• Q4 2024 sales projected lower than Q3 due to lack of major OEM and Filshie orders.

• Adjusted EBITDA for full year 2024 expected in the $19–20M range.